Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)
Cyclobenzaprine Hydrochloride
Product Images NDC 53002-0521
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 53002-0521). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
This is a table showing the results of a study on the effects of Cyclobenzaprine HCI Tablets on symptoms such as drowsiness, dry mouth, fatigue, and headache. The study involved two groups of patients taking 5mg and 10mg of the medication and a third group taking a placebo. The results show the percentage of patients in each group who experienced each symptom.*
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
This text provides information about the side effects observed during clinical studies and surveillance programs with Cyclobenzaprine HCI Tablets at a dosage of 10mg. The most common side effect reported in clinical studies was drowsiness (39%), followed by dry mouth (2%) and dizziness (1%). The surveillance program also showed high incidence rates for drowsiness (16%), followed by dry mouth (7%) and dizziness (3%).*
Label Image (Lbl530020521)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
